3 results
Approved WMORecruiting
Primary:To evaluate the efficacy of ruxolitinib cream in participants with vitiligo.Secondary:To further assess the efficacy of ruxolitinib cream.To evaluate the safety and tolerability of ruxolitinib cream.To evaluate the ruxolitinib PK in plasma…
Approved WMOPending
Primary Objective:To evaluate the duration of clinical response of ruxolitinib cream in participants with vitiligo.
Approved WMORecruiting
We hypothesize that Kenalog-40, Kenalog-10 and Depo-Medrol 40 mg/ml have a different effectiveness in treating trigger fingers in both primary as secondary outcomes.